Galectin-3: A possible complementary marker to the PSA blood test

Oncotarget

Volumn 4, Issue 4, 2013, Pages 542-549

  Balan, Vitaly ^a   Wang, Yi ^a   Nangia Makker, Pratima ^a   Kho, Dhonghyo ^a   Bajaj, Madhuri ^a   Smith, Daryn ^a   Heilbrun, Lance ^a   Raz, Avraham ^a   Heath, Elisabeth ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood test; Cleavage; Galectin 3; Psa

Indexed keywords

GALECTIN 3; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD EXAMINATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; TISSUE LEVEL; TISSUE MICROARRAY;

EID: 84879175055     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.923     Document Type: Article

References (48)

1. Young CY, Andrews PE, Montgomery BT and Tindall DJ. Tissue-specific and hormonal regulation of human prostatespecific glandular kallikrein. Biochemistry (Mosc). 1992; 31(3):818-824.
2. Schalken JA. Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia. BJU Int. 2004; 93 Suppl 1:5-9.
3. Lilja H. Biology of prostate-specific antigen. Urology. 2003; 62(5 Suppl 1):27-33.
4. Ward AM, Catto JW and Hamdy FC. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem. 2001; 38(Pt 6):633-651.
5. Hirabayashi J and Kasai KI. Evolution of animal lectins. Prog Mol Subcell Biol. 1998; 19:45-88.
6. Barondes SH, Cooper DN, Gitt MA and Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994; 269(33):20807-20810.
7. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C and Kasai K. Galectins: a family of animal beta-galactosidebinding lectins. Cell. 1994; 76(4):597-598.
8. Lepur A, Salomonsson E, Nilsson UJ and Leffler H. Ligand induced galectin-3 protein self-association. J Biol Chem. 2012; 287(26):21751-21756.
9. Seetharaman J, Kanigsberg A, Slaaby R, Leffler H, Barondes SH and Rini JM. X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. J Biol Chem. 1998; 273(21):13047-13052.
10. Strik HM, Deininger MH, Frank B, Schluesener HJ and Meyermann R. Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas. J Neurooncol. 2001; 53(1):13-20.
11. Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F and Wang JL. Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology. 2002; 12(5):329-337.
12. Yu F, Finley RL, Jr., Raz A and Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem. 2002; 277(18):15819-15827.
13. Cummings RD and Liu FT. (2009). Galectins. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW and Etzler ME, eds. Essentials of Glycobiology. (Cold Spring Harbor (NY).
14. Dumic J, Dabelic S and Flögel M. Galectin-3: an openended story. Biochim Biophys Acta. 2006; 1760(4):616-635.
15. Chen HY, Liu FT and Yang RY. Roles of galectin-3 in immune responses. Arch Immunol Ther Exp (Warsz). 2005; 53(6):497-504.
16. Takenaka Y, Fukumori T and Raz A. Galectin-3 and metastasis. Glycoconj J. 2004; 19(7-9):543-549.
17. Shekhar MP, Nangia-Makker P, Tait L, Miller F and Raz A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol. 2004; 165(6):1931-1941.
18. Puglisi F, Minisini AM, Barbone F, Intersimone D, Aprile G, Puppin C, Damante G, Paron I, Tell G, Piga A, Di Loreto C. Galectin-3 expression in non-small cell lung carcinoma. Cancer Lett. 2004; 212(2):233-239.
19. Califice S, Castronovo V, Van Den Brule F. Galectin-3 and cancer. Int J Oncol. 2004; 25(4):983-992.
20. Balan V, Nangia-Makker P and Raz A. Galectins as Cancer Biomarkers. 2010:1-19.
21. Newlaczyl AU and Yu LG. Galectin-3 - A jack-of-all-trades in cancer. Cancer Lett. 2011.
22. Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta. 1999; 1473(1):172-185.
23. Chirico WJ. Protein release through nonlethal oncotic pores as an alternative nonclassical secretory pathway. Bmc Cell Biology. 2011; 12.
24. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Di Virgilio F. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol. 2006; 176(7):3877-3883.
25. Baptiste TA, James A, Saria M and Ochieng J. Mechanotransduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extracellular functions of the lectin. Exp Cell Res. 2007; 313(4):652-664.
26. Ochieng J, Furtak V and Lukyanov P. Extracellular functions of galectin-3. Glycoconj J. 2004; 19(7-9):527-535.
27. Nangia-Makker P, Balan V and Raz A. Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron. 2008; 1(1):43-51.
28. Van Den Brule FA, Waltregny D, Liu FT, Castronovo V. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer. 2000; 89(4):361-367.
29. Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, Pienta KJ and Raz A. Regulation of prostate cancer progression by galectin-3. Am J Pathol. 2009; 174(4):1515-1523.
30. Balan V, Nangia-Makker P, Jung YS, Wang Y Raz A. Galectin-3: A novel substrate for c-Abl kinase. Biochim Biophys Acta. 2010; 1803(10):1198-1205.
31. Saraswati S, Block AS, Davidson MK, Rank RG, Mahadevan M and Diekman AB. Galectin-3 is a substrate for prostate specific antigen (PSA) in human seminal plasma. The Prostate. 2011; 71(2):197-208.
32. Balan V, Nangia-Makker P, Kho DH, Wang Y and Raz A. Tyrosine-phosphorylated galectin-3 protein is resistant to prostate-specific antigen (PSA) cleavage. J Biol Chem. 2012; 287(8):5192-5198.
33. Wang Y, Nangia-Makker P, Balan V, Hogan V and Raz A. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell death & disease. 2010; 1(11):e101.
34. Brehmer B, Biesterfeld S and Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis. 2003; 6(3):217-222.
35. Rabinovich GA, Toscano MA, Jackson SS and Vasta GR. Functions of cell surface galectin-glycoprotein lattices. Curr Opin Struct Biol. 2007; 17(5):513-520.
36. John CM, Leffler H, Kahl-Knutsson B, Svensson I and Jarvis GA. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res. 2003; 9(6):2374-2383.
37. Vereecken P, Awada A, Suciu S, Castro G, Morandini R, Litynska A, Lienard D, Ezzedine K, Ghanem G and Heenen M. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res. 2009; 19(5):316-320.
38. Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, Andre S, Gabius HJ and Laurent G. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid. 2008; 18(7):705-712.
39. Sakaki M, Oka N, Nakanishi R, Yamaguchi K, Fukumori T and Kanayama HO. Serum level of galectin-3 in human bladder cancer. J Med Invest. 2008; 55(1-2):127-132.
40. Kim SJ, Lee SJ, Sung HJ, Choi IK, Choi CW, Kim BS, Kim JS, Yu W, Hwang HS and Kim IS. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas. Acta Haematol. 2008; 120(4):211-216.
41. Inohara H, Segawa T, Miyauchi A, Yoshii T, Nakahara S, Raz A, Maeda M, Miyoshi E, Kinoshita N, Yoshida H, Furukawa M, Takenaka Y, Takamura Y, Ito Y and Taniguchi N. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun. 2008; 376(3):605-610.
42. Vereecken P, Heenen M, Babar S and Van Baren N. Is serum galectin-3 a potential predictor of the response to active specific immunotherapy in melanoma patients J Eur Acad Dermatol Venereol. 2007; 21(2):278-280.
43. Barrow H, Rhodes JM and Yu LG. Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients. Cell Oncol (Dordr). 2012.
44. Xie L, Ni WK, Chen XD, Xiao MB, Chen BY, He S, Lu CH, Li XY, Jiang F and Ni RZ. The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol. 2012; 138(6):1035-1043.
45. Barykova YA, Logunov DY, Shmarov MM, Vinarov AZ, Fiev DN, Vinarova NA, Rakovskaya IV, Baker PS, Shyshynova I, Stephenson AJ, Klein EA, Naroditsky BS, Gintsburg AL and Gudkov AV. Association of Mycoplasma hominis infection with prostate cancer. Oncotarget. 2011; 2(4):289-297.
46. Banerjee SR, Pullambhatla M, Shallal H, Lisok A, Mease RC and Pomper MG. A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). Oncotarget. 2011; 2(12):1244-1253.
47. Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y, Ito Y, Hirano H, Inayama Y, Aoki I, Nagashima Y, Kubota Y and Ishiguro H. Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget. 2012; 3(11):1455-1471.
48. Hintze J. Power and Sample Size (PASS) 11. NCSS, LLC. Kaysville, Utah, USA. 2011.